BioAtla is a series c plus startup based in United States. 1 investor tracked.
BioAtla is a startup founded in 2016 based in the United States. Its most recent tracked round is Series-c-plus. Brouky records 1 investor associated with the company.
BioAtla is a clinical-stage biopharmaceutical company that develops therapies for cancer using its Conditionally Active Biologics (CAB) platform. The CAB platform is designed to exploit the tumor microenvironment to selectively activate biologic drugs in diseased tissue.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.